XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1

Segments (Tables)

3 Months Ended

Mar. 31, 2022

Summary of Segment Profit

		Three months ended March 31,
		2022
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,737			$	1,156			$	492
Gross profit			890				694				286
R&D expenses			143				58				20
S&M expenses			245				196				97
G&A expenses			112				59				29
Other income			(11	)			§				(40	)
Segment profit		$	402			$	381			$	179

§ Represents an amount less than $0.5 million.

		Three months ended March 31,
		2021
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,989			$	1,214			$	490
Gross profit			1,074				688				260
R&D expenses			160				66				18
S&M expenses			229				214				96
G&A expenses			111				70				26
Other income			(3	)			§				(2	)
Segment profit		$	577			$	338			$	122

§ Represents an amount less than $0.5 million.

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2022 and 2021:

		Three months ended
		March 31,
		2022				2021
		(U.S. $ in millions)
North America profit		$	402			$	577
Europe profit			381				338
International Markets profit			179				122
Total reportable segments profit			962				1,036
Profit of other activities			52				41
Total segments profit			1,013				1,077
Amounts not allocated to segments:
Amortization			200				242

Other assets impairments, restructuring and other items			128				137
Intangible assets impairments			149				79
Legal settlements and loss contingencies			1,124				104
Other unallocated amounts			127				82
Consolidated operating income (loss)			(713	)			434
Financial expenses, net			258				290
Consolidated income (loss) before income taxes		$	(971	)		$	144

Schedule of Net Sales by Product Line

North America		Three months ended March 31,
		2022				2021
		(U.S. $ in millions)
Generic products		$	899			$	1,053
AJOVY			36				31
AUSTEDO			154				146
BENDEKA®/TREANDA®			82				91
COPAXONE			86				164
Anda			342				289
Other			139				215
Total		$	1,737			$	1,989

Europe		Three months ended March 31,
		2022				2021
		(U.S. $ in millions)
Generic products		$	876			$	865
AJOVY			30				16
COPAXONE			72				100
Respiratory products			71				93
Other			107				140
Total		$	1,156			$	1,214

International markets		Three months ended March 31,
		2022				2021
		(U.S. $ in millions)
Generic products		$	388			$	392
AJOVY			6				1
COPAXONE			10				12
Other			88				85
Total		$	492			$	490

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration